Mobile Site ›

The Classic Myeloproliferative Neoplasms

Optimizing Laboratory Testing for Hematologic Disorders Series



JAK2 Exon 12 Sequencing: When Not to Use

Slide 18

October 2011

Well, it’s quite clear when we should not do JAK2 exon 12 sequencing. It should not be used as the routine JAK2 screening method in a possible myeloproliferative neoplasm for reasons that I pointed out in the previous slide. Because of the infrequency of exon 12 mutations, sequencing studies should not be done until the much more common JAK2 V617F results are available and, since JAK2 exon 12 mutations occur almost exclusively in PV, these studies should not be done unless the CBC and serum erythropoietin studies raise the possibility of a PV.

Exon 12 Sequencing: When Not to Use

 


Jump to section:


Key